Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice
I am satisfied with this product
Its helpful to understand what youre seeing
Weight-loss drugs may treat Long COVID Lead researcher Dr Julia Moore Vogel joined me on the podcast to explain the LoCITT-T trial, studying tirzepatide for moderate to severe LC
No referral is required
If it continues dropping, add more
US$ 27.85
US$ 21.28
US$ 27.96
